

brisbane diamantina
health partners

Innovative healthcare through partnerships



Brisbane Cancer Conference

Thursday 23 November – Friday 24 November 2017
Brisbane Convention and Exhibition Centre



PA Research
Foundation
At the home of the world's first cancer vaccine

CONFERENCE HANDBOOK

CONFERENCE SPONSORS

Platinum Sponsor



Gold Sponsors



Silver Sponsors



Bronze Sponsors



Donations



WELCOME

brisbane diamantina
health partners



11th November 2017

Dear Friends and Colleagues,

Welcome to the 4th Brisbane Cancer Conference. With the establishment of the Brisbane Diamantina Health Partners as an NHMRC Advanced Health Research and Translation Centre, this meeting provides a unique opportunity to advance cancer research in Brisbane and Queensland. The meeting comprises plenary lectures and workshops covering recent scientific, technological, nursing and medical advances in the diagnosis and treatment of malignant disease and ongoing research in our state.

On Thursday 23rd November the meeting will start with Breast Cancer, Prostate Cancer and Immunotherapy symposia running from 8am – 12pm. There will be an industry supported immunoncology session at lunch-time followed by plenary lectures from 2pm – 4pm and subsequently workshops in these areas running from 4.30pm – 6.30pm.

A symposium dinner will be held on Thursday evening offering the opportunity to socialise with colleagues from institutions throughout the city and Queensland.

The all-day session on 24th November will include plenary lectures followed by tumour-site specific workshops in the morning and afternoon. A key session will be lectures by Queensland oncology researchers that are contributing to global advances in our understanding of the epidemiology, molecular biology and treatment of malignant disease.

Approximately 900 people registered for the event last year demonstrating the value of a truly multidisciplinary annual Queensland Translational Cancer Conference in Brisbane.

This conference is made possible through the support of the PA Research Foundation, Brisbane Diamantina Health Partners, Translational Research Institute, QUT/IHBI, Mater Research, ICON, QIMR Berghofer, our industry sponsors, the time and effort of the chairs who put the workshops together as well as Therese, the QUT Cancer and Ageing Research Program (CARP) team and the many other volunteers whose efforts have made this annual event a reality.

Best wishes for what should be an enjoyable and fulfilling two days.

Yours sincerely,

Professor Ken O'Byrne

CONFERENCE PROGRAM

DAY
1

Thursday 23 November 2017

Morning Symposia

Breast Cancer Symposium (supported by Roche)

Boulevard Room

Chairs: Nicola Lowrey, Fiona Simpson

8.00am	Presenting your work to consumers – Fran Boyle
8.30am	Bioinformatic and functional evaluation of rare variants in the 5' region of cancer susceptibility genes – Lez Burke
8.48am	Causes and consequences of WDHD1 overexpression in breast cancer – Pacal Dujiff
9.06am	Diet, exercise & weight management in early-stage and metastatic breast cancer – Marina Reeves
9.24am	Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials – Liz Eakin
9.42am	Targets and directions in breast cancer clinical trials – Cath Shannon
	Morning tea
10:30-12:00	Translational Breast Cancer Research in Australia Chair: Rik Thompson
10.30am	Exploring new therapies for breast cancer brain metastasis in clinically-relevant syngeneic models – Normand Pouliot
11.10am	Metastatic breast cancer: changing clinical paradigms – Fran Boyle
11.50am	Discussion – Translational questions/approaches in Metastatic Breast Cancer – Rik Thompson

Prostate Cancer (supported by Astellas)

Room B1 and B2

Chair: Colleen Nelson

Adaptive response

8.00am	Targeting the adaptive tumour plasticity response to androgen targeted therapies – Brett Hollier
8.30am	Understanding the Temporal Dynamics of EMT in prostate cancer – a Network-Based Approach – Ati Taherian Fard
8.45am	Macrophage contributions to metastatic prostate cancer impacts on the bone microenvironment – Allison Pettit
9.00am	Inhibition of Neuropilin-1 as a novel adjuvant therapy in advanced prostate cancer – Marianna Volpert
9.15am	Involvement of the kallikrein-related peptidase 14 in aggressiveness of prostate cancer cells – Thomas Kryza
9.30am	The lncRNA GHSROS mediates tumour growth and expression of genes associated with metastasis and adverse outcome – Patrick Thomas
9.45am	The long and short of a GWAS identified long noncoding RNA – Jyotna Batra
	Morning tea
10:30am	Targeting glutamine metabolism in prostate cancer – Jeff Holst
10.45am	Co-targeting metabolic dysfunction and tumour growth in a hyperinsulinaemic mouse model of prostate cancer – Penny Jeffery
11:00am	Cholesterol, lipid raft and exosomal miRNA in prostate cancer – Michelle Hill
11:15am	Targeting leptin in prostate cancer – Lisa Philp
11.30am	Targeting genetic instability in prostate cancer – Derek Richard
11.45am	Targeting lipid metabolism in prostate cancer: New therapeutic concepts with old drugs – Rohan Davis

Immuno-oncology (supported by AstraZeneca)

Room B3

Chairs: Jeremy Long, Riccardo Dolcetti

8.00am	Immunobiology – Tobias Bald
8.30am	Immunogenomics – Lutz Krause
8.50am	Imaging in Immunotherapy – Kenneth Miles

CONFERENCE PROGRAM

DAY
1

Thursday 23 November 2017

9.15am	Immunotherapy challenges: rare tumours – David Thomas
9.45am	Breakthrough in breast cancer – Nicole McCarthy
	Morning tea
10.30am	Immune checkpoint therapies and resistance mechanisms in haematological malignancies – Maher Gandhi
10.50am	Immunotherapy plus radiotherapy: the Abscopal effect – Renee Finnigan
11.10am	Novel immune checkpoint inhibitors – Michelle Wykes
11.30am	CAR-T cell therapies – Michael Brown
12.00pm	Lunch sponsored by MSD

Lunch-time Symposium

Lunch-time Symposium (supported by MSD)	
Boulevard Auditorium	Chair: Rajiv Khanna
12.30pm	Biomarkers in Immuno-oncology; now and the future – Caroline Cooper
1.00pm	Lessons learnt in the immunotherapy of malignant disease – Ken O'Byrne

1.30pm	Arrival refreshments
--------	----------------------

Afternoon Plenary Sessions

Plenary Thursday pm	
Boulevard Auditorium	
Session 1	Chairs: Robert Bowen, John Prins
2.00pm	BDHP and cancer – Euan Walpole
2.20pm	QGHA: where we are and where we are going – David Bunker
2.40pm	QGHA and Queensland pathology – Sunil Lahkani
Session 2	Chairs: Janet Hardy, Michael Kimlin
3.00pm	Palliative medicine – Will Cairns
3.20pm	Stereotactic radiosurgery – Ben Chua
3.40pm	Prevention of melanoma and skin cancer – David Whiteman
4.00pm	Tea and Coffee

Afternoon Workshops

Imaging	
Room A1	Chairs: Liz Kenny, Tom Lloyd
Imaging to guide therapy into the future	
4.30pm	MRI imaging in rectal cancer – Sonja Gustafson
4.50pm	HERF cancer imaging program – Paul Thomas
5.05pm	Theranostics program for CSIRO – Simon Puttick
5.20pm	LiRADS Managing Hepatocellular Imaging – Dave Leggett
5.35pm	Breast imaging – Karin Steinke
5.55pm	PSMA-PET-MR – Kenneth Miles
Discussion	

CONFERENCE PROGRAM

DAY
1

Thursday 23 November 2017

Genomics	
Room A2	Chair: John Pearson
4.30pm	The Australian Genomics ICon Flagship - Managing Patient Risk: Hereditary Cancer Syndromes – Uwe Dressel
4.50pm	The Mesothelioma Genomics Project (MesoGen) – Ann-Marie Patch
5.10pm	Artificial Intelligence and Machine Learning (AI/ML) and how can it help genomics – Nicholas Therkelsen-Terry
5.30pm	What is cloud and how can it help genomics? – Steve Nicoll
5.50pm	Evaluating the economics of clinical genomics – Louisa Gordon
Clinical Trials	
Room B1	Chairs: Adam Stoneley, Suzanne Elliott
Theme: Developments on the doorstep	
4.30pm	Introduction – Adam Stoneley
4.35pm	Bringing trials to remote locations – Adam Stoneley
4.55pm	Implementation of HREA – Melissa Hagan
5.15pm	ICH GCP E6 R2 updates workshop – Sophie Mepham
6.00pm	The truth about RBM – Elizabeth Wilson
6.20pm	Discussion Panel & Questions – Suzanne Elliott
Commercialisation	
Room B2	Chairs: Derek Richard, Mario Pennisi
4.30pm	Framework to coordinating interactions with international partners – Fares Al-Ejeh
4.45pm	Nematode diagnostic tests, Hirotsu Bio-Science Inc – Takaaki Hirotsu
5.00pm	CARP Pharmaceuticals – Derek Richard
5.15pm	First steps into commercialisation of a salivary diagnostic test: collaboration with MDxHealth – Chaminde Punyadeera
5.30pm	Admedus – Neil Finlayson
5.45pm	Engaging Foundations – John Fraser
6.00pm	The industry perspective: Question and answer session – Alan Paul, Astrazeneca, Ian Black, Roche and Chris Vearing, MSD Pharma
6.20pm	Discussion
Palliative Medicine	
Room B3	Chairs: Phillip Good, Patsy Yates
4.30pm	Identifying risk of deteriorating and dying in people with haematological malignancy – Elise Button
4.45pm	Methadone – what we have learnt from our PK studies – Rani George/Alison Haywood
5.00pm	Does dexamethasone improve dyspnoea? – a Cochrane review – Jacque Duc
5.15pm	Use of holistic needs assessment tool for hospice care of children at Hummingbird House – Ross Pinkerton
5.30pm	Research in medicinal cannabis – pitfalls and pearls – Phillip Good
5.45pm	Laughter and tears in interprofessional cancer care – Rebecca Olson
6.00pm	Discussion
7.00pm ‘til late	Gala Dinner, Sky Room, Brisbane Convention and Exhibition Centre

CONFERENCE PROGRAM

DAY
2

Friday 24 November 2017

Morning Plenary Session

Plenary Friday am	
Boulevard Auditorium	
Chairs: Robin Mortimer, Ian Irving	
8.00am	Personalised medicine in lung cancer – Margie McGrath
8.15am	Clinical Leadership in Translational Research – Lewis Perrin
8.30am	Oral Cancer surgery – who, what, how, why? – Martin Batstone
8.45am	Resection of liver metastases – Tom O'Rourke
9.00am	Theranostics for NETs tumours – David Wyld
9.15am	New avenues in immunotherapy – Riccardo Dolcetti
9.30am	Translational research in prostate cancer – Colleen Nelson
9.45am	The role of patient derived xenografts in cancer research – Elizabeth Williams
10.00am	Tea and Coffee

Morning Workshops

Brain Tumours	
Room A1	Chair: Mark Pinkham
10.30am	Investigating the HER2-3 dimer as a theranostic target in brain metastases – Jodi Saunus
10.45am	Role of systemic therapy in non-small cell lung cancer brain metastases – Robert Mason
11.00am	Radiological kinetics of brain metastases and clinical implications – Luke Nicholls
11.15am	Advances in radiosurgery for brain metastases – David Schlect
11.30am	Role of the Cancer Care Co-ordinator in the management of patients with brain metastases – Angela McBean
11.45am	Discussion
Novel Immunotherapies	
Room A2	Chair: Rajiv Khanna
10.30am	Solid tumour immunotherapy – Bill Dougall
10.43am	Brain cancer immunotherapy – David Walker
10.56am	T-cell therapy – Siok Tey
11.10am	Dendritic cell vaccines – Kristen Radford
11.25am	A nanoparticulate cancer vaccine targeting cross-presenting dendritic cells – Ranjeny Thomas
11.40am	Cytokine release assay: From toxicity to response – Antiopi Varelius
11.50am	Discussion
Thoracic Malignancies	
Room B1	Chairs: Henry Marshall, Simon Bowler
10.30am	Targeting therapy in thoracic oncology; tissue remains the issue – Suzanne Allan
10.38am	Optimising tissue collection for oncogene assessment – Michelle Murphy
10.46am	The role of the radiologist in tissue collection – Duncan Walker
10.54am	Pathology today and tomorrow – Cameron Snell
11.02am	Whole genome sequencing – Matt Brown
11.10am	CTCs – Arutha Kulasinghe
11.18am	'Lab-in-a-drop' – Matt Trau
11.28am	ctDNA – Glenn Francis
11.36am	Proteins in exosomes – Andreas Moller
11.44am	Familial lung cancer – Emma Duncan
11.52am	Discussion

CONFERENCE PROGRAM

DAY
2

Friday 24 November 2017

Survivorship	
Room B2	Chairs: Ray Chan, David Wyld
10.30am	Survivorship Interventions for Men with Prostate Cancer: Outcomes from the TrueNTH Pilot Study – Patsy Yates
10.50am	Cancer on the Margins: Experiences of Living with Neuroendocrine Tumours – David Wyld
11.10am	Healthy Living After Cancer Program – Liz Eakin
11.30am	Financial Toxicity in Cancer Survivors – Louisa Gordon
11.50am	Discussion
GU Malignancies	
Room B3	Chairs: Ian Vela, Jeff Goh
10.30am	Lu-PSMA/ Theranostics in metastatic CRPC – David Pattison
10.50am	Update on management of advanced urothelial/ bladder cancers – Aneta Suder
11.10am	Update on the management of advanced RCC – Jeff Goh
11.30am	Novel biomarkers in Renal Cell Cancer – Glenda Gobe
11.50am	Discussion
Gynae-oncology	
Boulevard Room	Chairs: Lewis Perrin, Pam Pollock, Monika Janda
10.30am	Opening Remarks – Pam Pollock
10.33am	Update of Immunology and Cervical Cancer Vaccines – Janin Chandra
10.57am	MRI Spectroscopy and Diagnosis of Ovarian Cancer – Peter Malycha
11.09am	Inhibition of Epigenetic Modifying Enzymes: A Preclinical Model for Ovarian Cancer – Jason Lee
11.21am	Sentinel Node Biopsy and Endometrial Cancer – Nisha Jagasia
11.33am	Intraepithelial Endometrial Cancer – Andreas Obermair
11.45am	Genomic Changes in Gestational Trophoblastic Disease – Andrea Garrett
11.57am	Closing Remarks – Monika Janda
Pharmacy	
Boulevard Auditorium	Chairs: Dan McKavanagh, Emily Wenta
Topic: Brisbane Cancer Pharmacy – Service Snapshots	
Cancer Pharmacy in Queensland is at the cutting edge of service delivery, with many pharmacies providing expert care in large clinics, using innovative systems, and managing complicated clinical presentations. This session will provide a snapshot from some of these pharmacies and a great opportunity to share innovative models of practice.	
10.30am	The 2017 COSA Guidelines – an update for cancer pharmacists – Christine Carrington
10.45am	Princess Alexandra Hospital – Kate Ross
11.00am	Icon Cancer Care <ul style="list-style-type: none"> Wesley Hospital/Regional – Jodie Lyons South Brisbane – Braedon Denham
11.30am	Royal Brisbane & Women's Hospital – Paul Klages
11.45am	Discussion
12.00pm	Tea and Coffee

Lunch-time Plenary Session

Plenary Friday lunch-time	
Boulevard Auditorium	Chairs: Frank Gannon, Stephen Ayre
12.30pm	Genomics and bioinformatics: now and the future – Nic Waddell
12.50pm	Melanoma and the immune revolution in cancer care – Victoria Atkinson
1.10pm	Personalised medicine in haematology – Geoff Hill
1.30pm	Overview of cancer Survivorship Research in Queensland – Ray Chan
2.00pm	Tea and Coffee

CONFERENCE PROGRAM

DAY
2

Friday 24 November 2017

Afternoon Workshops

Small 3D Cancer Models	
Room A1	Chair: Laura Bray, Jacqui McGovern
2.30-2.32	Overview of the agenda, goals for the day – Laura Bray
2.32-3.15	3D in vitro cancer models <ol style="list-style-type: none"> 1. Real-time cell cycle imaging in a 3D cell culture models of melanoma – Loredana Spoerri 2. Hydrogels for 3D cell culture and cancer models – Christoph Meinert 3. Developing a bioengineered 3D model to study the role of bone marrow adipocytes in prostate cancer bone metastasis – Joan Röhl 4. Microscopy techniques for cancer imaging – Sandrine Roy
3.15-4.00	3D in vivo cancer models <ol style="list-style-type: none"> 1. Studying mitotic and chromosome segregation defects in in vitro and in vivo 3D cancer models – Pascal Duiff 2. Animal model to study immune regulation of prostate cancer tumour bone microenvironment – Andy Wu 3. Humanised mouse models to evaluate new cancer immunotherapies – Oscar Haigh 4. Tissue-engineering an in vivo humanized bone model for cancer applications – Jacqui McGovern
Breast Cancer	
Room A2	Chairs: Katharine Cuff, Fiona Simpson, Juliet French, Nicola Lowrey, Rik Thompson
2.30pm	The genomic landscape of familial breast cancer – Pete Simpson
2.50pm	Synergistic radiotherapy treatment with immunotherapeutic agents for triple negative breast cancer – Preliminary preclinical results – Davide Fontanarosa
3.10pm	Oncogenic transposon activation in breast cancer – Kyle Upton
3.30pm	Some new nanotechnologies for personalising cancer diagnostics – Matt Trau
3.50pm	Discussion – Optimising breast cancer research in Brisbane
Melanoma and Skin Cancer	
Room B1	Chairs: Peter Soyer, Nikolas Haass
2.30pm	Duality of proliferative behaviour in the interfollicular epidermis upon chronic UV irradiation: implications for carcinogenesis – Edwige Roy
2.40pm	Translating melanoma genomic data using high-content imaging of melanocyte-keratinocyte interaction – Dubravka Škalamera
2.50pm	Melanoma-microRNAs as novel disease biomarkers – Mitchell Stark
3.00pm	BRN2-MITF phenotype switching in melanoma cells promotes invasion and metabolic adaptation to micro-environmental cues – Yash Chhabra
3.10pm	NDRG1-mediated down-regulation of MITF drives dynamic heterogeneity in melanoma spheroids – Farzana Ahmed
3.20pm	Novel targets of BRN2 contributing to melanoma metastasis – Glen Boyle
3.30pm	PTEN mutant melanomas exhibit a drug-resistant cell state but are responsive to AKT inhibition – Ken Dutton-Regester
3.40pm	H3K4me3 remodeling drives escape from the BRAF inhibitor induced slow cycling phenotype – Heinz Hammerlindl
3.50pm	HGF/c-MET signalling a resistance mechanism to immunotherapy – Tobias Bald

CONFERENCE PROGRAM

DAY
2

Friday 24 November 2017

Head and Neck Cancer

Room B2

Chairs: Rahul Ladwa, Chris Perry

2.30pm	Updates on systemic therapy in Head and Neck cancer – Brett Hughes
2.38pm	H-IMRT data from their respective fields – Laura Moroney & Claire Blake
2.46pm	The expanding role of trans-oro-robotic surgery (Pathos Trial) – Matthew Ward
2.54pm	Reconstruction post head and neck cancer surgery – Milap Rogani
3.02pm	Demographics of HPV associated oro-pharyngeal cancer – Anneke Antonsson
3.10pm	Discussion
3.20pm	New systemic trials <ul style="list-style-type: none"> • Stemetil proof of principle and current phase I trial – Fiona Simpson • EBC 46 lab work and phase 1 EBC 46 trial – Courtney Henrys • Phase II study on a therapeutic vaccine for HPV+ oropharyngeal cancer – Janin Chandra
3.32pm	Advances in vocal rehabilitation after laryngectomy – Bena Cartmill/Kelli Hancock
3.40pm	Liquid biopsies in Head and Neck cancer – Kai Tang
3.48pm	Discussion

Haematology

Room B3

Chair: Colm Keane, Steven Lane

2.30pm	Improving GVL with Interferon post-allogeneic Bone Marrow Transplant – Andrea Henden
2.45pm	Update on Amyloidosis – Peter Mollee
3.00pm	The Preclinical Efficacy of a Novel Telomerase Inhibitor, Imetelstat, in Acute Myeloid Leukaemia: a Randomized Trial in Patient-Derived Xenografts – Claudia Bruedigam
3.15pm	The Tumour Microenvironment is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma – Joshua Tobin
3.30pm	Update on BDHP clinical trials network for Haematology – Steven Lane
3.45pm	Discussion

GI Malignancies

Boulevard Room

Chair: Chris Gillespie, Vikram Jain

Theme: Identifying clinical research opportunities through audit and the laboratory

2.30pm	Fund raising for gastro-intestinal tract cancers in Brisbane – Damian Topp
2.40pm	Rectal cancer audit update – Vikram Jain & Chris Gillespie
2.50pm	Resection of colorectal metastases – the uncertainty principle – Andrew Robson
3.00pm	Discussion
3.10pm	Peritonectomy in Brisbane – Sanjeev Naidu
3.20pm	Neoadjuvant pancreatic cancer study – Warren Joubert
3.30pm	The genomic landscape of oesophageal adenocarcinoma – Felicity Newell
3.40pm	Targeting MUC13 to sensitise colorectal cancers to chemotherapy and immunotherapy – Yong Sheng
3.50pm	Discussion
4.00pm	Refreshment Break

Evening Plenary Session




Plenary Friday evening - Big data

Boulevard Auditorium


Chairs: Michael Cleary, David Theile

4.10pm	Google Bio-informatics – TBC
4.25pm	IBM-Watson – Terry Sweeney
4.40pm	Queensland Health Road Map Big Data; Shaping Our Future – Richard Ashby
4.55pm	Discussion
5.15pm	Wine and Cheese
6.00pm	Exit

VENUE FLOOR PLANS



SPONSOR FLOOR PLAN



MSD	10
Astrazeneca	9
Roche	11
Bristol Myers Squibb	12
Pfizer	7
Merck	1
Ipsen	2
Astellas	3
Novartis	4
Teva	5

Janssen	6
Menarini	8
IQVIA	13
Sumitomo	14
Essen/Abacus	15
Aspen	16
Agena Bioscience	17
Specialized Therapeutics Australia	18

Brisbane Cancer Conference

Thursday, 23 November – Friday 24 November 2017
Brisbane Convention and Exhibition Centre

brisbane diamantina
health partners

Innovative healthcare through partnerships

